SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Encysive Pharmaceuticals (ENCY)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (197)6/26/2007 1:51:34 PM
From: tuck  Read Replies (1) of 205
 
One very slight silver lining was the black box label for Lentairis (Ambrisentan) because of liver tox potential. Patients have to be monitored once per month. Would Thelin have gotten a black box, too, had the FDA approved it? If not, there's still some hope for Thelin to compete, but apparently not much. Unless the dispute process works out, and fairly quickly, it would take a partner and a new trial. By which time competitors get entrenched, and the clock ticks on the patents.

This would be a value play except for the debt.

Arrggghhh.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News